- Company to host conference call at 3 pm CEST (9 am EDT) today to review study results
- First RSV vaccine to show immunogenicity against five distinct RSV proteins
- 421 subject study shows vaccine was well tolerated at all doses and regimes investigated
- Single vaccination regime selected to induce a broad antibody and T cell response in elderly subjects
- Results confirm the induction of antibodies (IgA) associated with mucosal responses - the site of RSV infection
COPENHAGEN, Denmark, June 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced positive results for MVA-BN ® RSV, a universal vaccine candidate designed to induce protective immune responses against both RSV subtypes (A & B). The vaccine was shown to be both well tolerated and immunogenic at both dose levels investigated. The study confirmed the hypothesis that MVA-BN RSV is the first vaccine candidate designed to induce a broad and robust immune response against five distinct RSV proteins following a single shot or booster vaccination, using Bavarian's proprietary viral platform MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic).
The randomized, placebo-controlled study enrolled 421 subjects aged 55 and older, at 12 centers across the United States. These subjects were enrolled into four active arms of the study, which examined the effects of both a high (5x10 8 ) and low (1x10 8 ) dose, administered as either one or two vaccinations (day 0, 28) and compared to a placebo arm.
A single vaccination induced the highest booster responses in both antibodies and T cells against RSV compared to a prime-boost regime. Compared to the subjects receiving placebo, a significant boost (2-4 fold) in antibodies was observed 2 weeks post the single booster vaccination. This included neutralizing and total antibodies (IgG) against RSV, as well as IgA antibodies, which are associated with mucosal responses and are thought to play an important role in protection against RSV. Significant T cell responses (5-10 fold) to all five RSV proteins were observed in the majority of subjects 1 week post the single booster vaccination.
At the 3 month time point post vaccination the immune responses induced by the two active doses investigated demonstrated significant boosts over placebo. Immune responses were seen to be similar across all active doses, potentially confirming the results seen with the 1x10 8 dose tested in a Phase 1 which also demonstrated durable antibody responses 6 months post vaccination.
Blood samples from the 6 month time point post vaccination are currently being tested in this Phase 2 study. Subjects that received a single vaccination with either dose will be given an additional booster later this year and followed for another RSV season, to help establish the immune responses 12 months post vaccination and the effect of another booster vaccination.
"Like influenza, RSV is associated with thousands of deaths in older adults annually in the U.S.," Steven J. Lawrence, MD, MSc, Associate Professor of Medicine, Division of Infectious Diseases, Washington University School of Medicine, and National Coordinating Investigator of the study remarked. "However unlike influenza, there are currently no licensed vaccines to protect against RSV. RSV vaccines have been elusive because of unique interactions the virus has with the human immune system making older vaccine technologies unsuccessful. A safe and effective vaccine to prevent complications of RSV could have a substantial impact on keeping older adults healthy."
"These Phase 2 data have confirmed that our universal RSV vaccine performed as we intended and induced a broad immune response against multiple targets of RSV, more than any other previous RSV vaccine candidate tested to date. Another important differentiating factor is that our vaccine is built upon our MVA platform and as such has also induced a robust T-cell response against five RSV proteins and a mucosal immune response, which is another parameter that has been largely ignored in previous attempts to develop a prophylactic RSV vaccine." said Paul Chaplin, President and CEO of Bavarian Nordic.
Conference call and webcast The management of Bavarian Nordic will host a conference call today at 3:00 pm CEST (9:00 am EDT) to review the results followed by a Q&A session. Dial-in numbers for the conference call are: Denmark: +45 32 71 16 59, UK: +44 (0) 20 3427 1907, USA: +1 212 444 0412. Participant code is 2814609. A live and archived webcast of the call and relevant slides will be available at http://www.bavarian-nordic.com/investor/event...event=5246
About Bavarian Nordic Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE ® , which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX ® ) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC ® , which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic .
Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts Rolf Sass Sørensen Vice President Investor Relations (EU) Tel: +45 61 77 47 43
Seth Lewis Vice President Investor Relations (US) Tel: +1 978 341 5271
Company Announcement no. 18 / 2017
Attachments:
